Shire plc (SHPG) Shares are Up 1.1%

Shire plc (SHPG) : Traders are bullish on Shire plc (SHPG) as it has outperformed the S&P 500 by a margin of 9.17% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.48%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.1% in the last 1 week, and is up 16.54% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Shire plc (NASDAQ:SHPG): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $192.29 and $191.62 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $193.87. The buying momentum continued till the end and the stock did not give up its gains. It closed at $193.49, notching a gain of 0.02% for the day. The total traded volume was 836,203 . The stock had closed at $193.46 on the previous day.


The stock has recorded a 20-day Moving Average of 4.09% and the 50-Day Moving Average is 5.64%. Shire plc is up 4.5% in the last 3-month period. Year-to-Date the stock performance stands at -5.22%.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.